NASDAQ:PGEN Precigen Q1 2024 Earnings Report $1.86 +0.03 (+1.37%) As of 10:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Precigen EPS ResultsActual EPS-$0.10Consensus EPS -$0.09Beat/MissMissed by -$0.01One Year Ago EPS-$0.10Precigen Revenue ResultsActual Revenue$1.07 millionExpected Revenue$1.54 millionBeat/MissMissed by -$470.00 thousandYoY Revenue GrowthN/APrecigen Announcement DetailsQuarterQ1 2024Date5/14/2024TimeAfter Market ClosesConference Call DateTuesday, May 14, 2024Conference Call Time4:00PM ETUpcoming EarningsPrecigen's Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Precigen Earnings HeadlinesPrecigen: August Is Pivotal For This Biotech InnovatorJuly 7, 2025 | seekingalpha.comPrecigen, Inc. (PGEN) Latest Stock News & Headlines - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 14 at 2:00 AM | Brownstone Research (Ad)Precigen Announces Key Approvals at Annual MeetingJuly 2, 2025 | theglobeandmail.comPrecigen, Inc.'s (NASDAQ:PGEN) market cap touched US$455m last week, benefiting both private equity firms who own 33% as well as institutionsJune 12, 2025 | finance.yahoo.comJ.P. Morgan Sticks to Its Sell Rating for Precigen (PGEN)May 20, 2025 | theglobeandmail.comSee More Precigen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Precigen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precigen and other key companies, straight to your email. Email Address About PrecigenPrecigen (NASDAQ:PGEN) (NASDAQ: PGEN) is a clinical-stage biotechnology company headquartered in Germantown, Maryland, that specializes in the development and commercialization of precision gene and cell therapies. Originally founded as Intrexon Corporation in 1998 by entrepreneur Randal Kirk, the company rebranded to Precigen in 2019 to reflect its concentrated focus on human health and immuno-oncology. Leveraging proprietary technologies such as AAV-based gene delivery platforms and engineered cell therapy systems, Precigen aims to address unmet medical needs in oncology, infectious diseases and inherited disorders. Precigen’s lead clinical programs include PRGN-3006, a modular chimeric antigen receptor (CAR) T-cell therapy targeting acute myeloid leukemia, and PRGN-2009, an investigational therapeutic for HPV-driven malignancies. In addition, the company is advancing gene-editing strategies for sickle cell disease and other hematologic conditions. Its preclinical portfolio spans novel vector design, synthetic biology approaches and next-generation immunomodulators, all designed to improve specificity, efficacy and safety of treatments in both solid tumors and rare genetic diseases. With research facilities in Maryland and a manufacturing center in Germantown, Precigen collaborates with academic institutions, contract development partners and global regulators to support its development programs. The company’s leadership team is headed by President and CEO Cedrik Britten, supported by Executive Chair Dr. Helen Sabzevari, MD, who brings extensive experience in oncology drug development. As a publicly traded entity on the Nasdaq exchange, Precigen combines a rich scientific heritage with a streamlined corporate structure dedicated to bringing transformative therapies to patients worldwide.Written by Jeffrey Neal JohnsonView Precigen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s Next Upcoming Earnings America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025)ASML (7/16/2025)Bank of America (7/16/2025)The Goldman Sachs Group (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
